

# Facts and Figures of NGFN-Plus / NGFN-Transfer 2008 - 2013

The German National Genome Research Network (NGFN) is the largest project of genome research funded by the German Federal Ministry of Education and Research (BMBF). With NGFN-Plus and NGFN-Transfer in the Program of Medical Genome Research the NGFN is now in its third and last period of funding (2008-2013).

On the following pages we would like to present the scientific success of NGFN-Plus and NGFN-Transfer. You will find information about the number of publications, patents and research awards as well as an overview of the internal and external networking of NGFN-Plus and NGFN-Transfer in the Program of Medical Genome Research. Moreover, we will provide data about the dimension of academic education and public relations of the network and finally give an overview of the number of publications released by the NGFN since its foundation in 2001.

National Genome Research Network (NGFN-Plus und NGFN-Transfer)  
NGFN Management Office  
c/o German Cancer Research Center  
Im Neuenheimer Feld 580, V025  
69120 Heidelberg  
Germany  
[info@ngfn.de](mailto:info@ngfn.de)

SPONSORED BY THE




## 1. Scientific Publications 2008 - 2013

### The publication output proves the scientific success of the NGFN

The Publication of research results is an important part of scientific work. Sharing the knowledge with other researchers helps finding new ways of disease control. The number of publications is a reliable indicator for scientific success of individual scientists as well as scientific programs.

Already in the first half-year of NGFN-Plus and NGFN-Transfer funding in the Program of Medical Genome Research starting in June 2008, 135 articles were published. In 2009, the number of articles released was almost triplicate, reaching 395. In the following years, the numbers of publications were still increasing to 535 in 2010 and to 608 in 2011. The reason for the slight decrease of the number of publications to 525 in 2012 and 247 in the first 5 months of 2013 is that in 2011 one third of the projects have been completed. In the course of 2013, all projects will be terminated.



SPONSORED BY THE



## 2. Publications in Top 20 Journals 2008 - 2013

### NGFN researchers publish at the scientific forefront

Between 2008 and May 2013, over 2,400 publications were released by NGFN scientists in the Program of Medical Genome Research, 170 of these were published in the 20 most important scientific journals. For the ranking of the journals an international criterion, the impact factor, is being used indicating the citation frequency of articles published in the respective journal. Hence it is a measure for the reputation of a scientific journal in the academic world.

The ranking shown in the following table is based on the impact factor for the year 2012 and shows the number of NGFN publications and the journals itemized by publication year.

**NGFN Publications in Top 20 Journals**

Rank 2012	Journal Title	IF 2012	2008*	2009	2010	2011	2012	2013**
2	New England Journal of Medicine	51,66		1	2	2	2	
5	Nature Reviews Genetics	41,06		1				
6	Lancet	39,06				2	3	1
7	Nature	38,60	2	4	6	8	12	1
8	Nature Reviews Molecular Cell Biology	37,16					1	1
11	Nature Genetics	35,21	12	17	24	21	14	9
12	Nature Reviews Cancer	35,00					1	
16	Nature Biotechnology	32,44	3		3			
17	Cell	31,96		1	1	3	3	1
18	Nature Reviews Neuroscience	31,67				1		
20	Science	31,03		2	3	1	1	
			17	26	39	38	37	13

\* 2<sup>nd</sup> half-year; \*\* until end of May

SPONSORED BY THE




### 3. Internal Collaborations 2008 - 2013

#### Networking leads to joint success

The collaboration of different NGFN-Plus Genome Networks and NGFN-Transfer Innovation Alliances is an important characteristic of such a big scientific network. Research groups working on scientifically distinct issues but with comparable technology as well as groups focusing on contiguous questions will have scientific exchange and collaborate with each other in order to more rapidly progress towards their goals and to concertedly answer research questions.

A measurable criterion for such NGFN internal networking is the number of joint publications. The following graph shows the network resulting from articles published jointly by several Genome Networks and Innovation Alliances. Cooperation between NGFN-Plus and NGFN-Transfer projects are indicated separately.



#### Genome Network and Innovation Alliances: Abbreviations

PHA: Atherogenomics	PKP: Prostate Cancer	PUD: DiGtoP
PHF: Obesity	PKT: Colorectal Cancer	PUH: MHC Sequencing
PHH: Heart Failure	PNA: Alzheimer's Disease	PUM: German Mouse Clinic
PIM: Herpes virus infection	PNE: Epilepsy and Migraine	PUU: Environment-related Diseases
PIR: RNomics in infection	PNM: Schizophrenia	TN: Cardiovascular Diseases and renal failure
PKB: Pancreatic Cancer	PNN: NeuroNet	TP: Protein Analysis of FFPE-samples
PKC: Colon Cancer	PNP: Parkinson's Disease	TS: Subgenome Fractionation
PKH: Brain Tumor	PNR: Mental Retardation	
PKL: Leukemia	PNS: Alcohol Addiction	
PKM: Mutanom	PUC: Cellular Systems Genomics	
PKN: Neuroblastoma		
PKO: Cancer Genes		


SPONSORED BY THE

## 4. Patents NGFN-1, NGFN-2, NGFN-Plus / -Transfer

### Taking the fast lane from research to utilization

The application of research results from NGFN-Plus and NGFN-Transfer is an important aim of the Program of Medical Genome Research. A crucial step for the practical application is the filing of patents for protectable inventions and developments. Therefore the number of patents is a measure for the utilization of NGFN research.

The diagram shows the number of patents granted in the respective funding periods of NGFN. For the current reporting period all 43 filed patents were counted.



### Patents of NGFN-Plus und NGFN-Transfer 2008 - 2013

#### Genome Network Obesity

Patent number: EP09014856.0

Title: A method for diagnosing metabolic syndrome, obesity and/or diabetes

Inventor: Schürmann-Bartsch, Scherneck, Vogel, Joost

Applicant: Deutsches Institut für Ernährungsforschung

State: withdrawn; Priority date: 30.11.2009

Patent number: EP12161060.4/ US 61/814,758 (**Together with Genome Network DiGtoP**)

Title: A novel method of producing an oocyte carrying a modified target sequence in its genome

Inventor: Kühn, Wurst, Meyer

Applicant: Helmholtz Zentrum München

State: Patent application filed and technology in commercial exploitation;

Priority date: 23.03.2012

SPONSORED BY THE



Patent number: EP13153142.8

Title: Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents

Inventor: S. Sauer, S. Holzhauser, R. Feldmann, A. Geikowski

Applicant: Max-Planck-Gesellschaft;

Priority date: 29.1.2013

Patent number: EP13165716.5

Title: PPARgamma Modulators

Inventor: S. Sauer, C. Weidner, M. Kliem

Applicant: Max-Planck-Gesellschaft, Priority date: 29.4.2013

### **Genome Network Heart Failure**

Patent number: US61/219,125

Title: Polynucleotides for diagnostic and prognostic of a cardiac disease

Inventor: Gotthardt, Hübner, Graeser, Guo

Applicant: MDC Berlin

State: Patent application filed and technology in commercial exploitation;

Priority date: 22.06.2009

### **Genome Network Herpes virus infection**

Patent number: EP11002480

Title: Micro RNA Inhibiting Nucleic Acid Molecule

Inventor: Lars Dölken, Ulrich Koszinowski, Sébastien Pfeffer

Applicant: Lars Dölken, LMU München

State: Released to the inventor; Priority date: 24.03.2011

Patent number: EP11306102.2

Title: MicroRNAs from human herpesvirus 6

Inventor: Lars Dölken, Sébastien Pfeffer, Lee Tuddenham, Jette Jung

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

State: Pending; Priority date: 06.09.2011

### **Genome Network Pancreatic Cancer**

Patent number: EP10001596.5

Title: Means and methods for diagnosing pancreatic cancer

Inventor: Christoph Schröder, Jörg Hoheisel, Tatjana Crnogorac-Jurcevic

Applicant: DKFZ Heidelberg

State: Pending; Priority date: 17.02.2010

Patent number: EP11169588.8

Title: Prediction of recurrence for superficial bladder cancer by protein signature in tissue samples

Inventor: Hoheisel, Radvanyi, Srinivasan, Schröder

Applicant: DKFZ und Institut Curie

State: Pending; Priority date: 10.06.2011

Patent number: US61/536,486

Title: Methods and composition involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease

Inventor: Alex Adai, Anna Szafranska-Schwarzbach, Bernard Andruss, Stephan Albrecht Hahn

Applicant: Universität Bochum, ASURAGEN

State: Released; Priority date: 19.09.2011

SPONSORED BY THE



Federal Ministry  
of Education  
and Research

Patent number: DE102011108254.2; DE102012005153.0

Title: Pantumormarker II (snRNA RNU2-1 as a tumor marker)

Inventor: A. Baraniskin, S. Hahn, W. Schmiegel

Applicant: Universität Bochum

State: Patent application filed and technology in commercial exploitation;

Priority date: 16.03.2012

### Genome Network Brain Tumor

Patent number: EP09006620.0

Title: Diagnostic methods for the prognosis of a brain tumor

Inventor: von Deimling, Hartmann, Zentgraf, Reifenberger, Capper, Weller, Wick

Applicant: DKFZ, Ruprecht-Karls-Universität Heidelberg

State: Pending; Priority date: 15.05.2009

Patent number: US61/334,812

Title: Methods for the diagnosis and prognosis of a tumor using BCAT1 protein

Inventor: Radlwimmer, Barbus, Tönjes, Tödt, Lichter, Reifenberger

Applicant: DKFZ Heidelberg

State: Pending; Priority date: 14.05.2010

Patent number: EP11000720.0

Title: Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia

Inventor: Bernhard Radlwimmer, Sebastian Barbus, Martje Tönjes, Peter Lichter

Applicant: DKFZ

State: Pending; Priority date: 28.01.2011

Patent number: US61/388,158; US61/503,950

Title: Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E

Inventor: von Deimling, Capper

Applicant: DKFZ, Ruprecht-Karls-Universität Heidelberg

State: Patent application filed and technology in commercial exploitation;

Priority date: 30.09.2010; 01.07.2011

### Genome Network Leukemia

Patent number: EP10004898.2

Title: Risk prognosis method for chronic lymphocytic leukemia

Inventor: Herold, Jurinovic, Buske, Bohlander

Applicant: Ludwig-Maximilians-Universität München

State: Pending; Priority date: 07.05.2010

### Genome Network Mutanom

Patent number: EP09158709.7

Title: Use of MLKL in cancer therapy

Inventor: Mollenhauer, Hudler, Blaich, Wittig

Applicant: DKFZ

State: Pending; Priority date: 24.04.2009

SPONSORED BY THE



Federal Ministry  
of Education  
and Research

### Genome Network Neuroblastoma

Patent number: DE102010024300.0 / DE102010024512.7

Title: Neue Ansätze für die Tumortherapie-Histondemethylasen

Inventor: PD Dr. Alexander Schramm, Dr. Johannes Schulte, Prof. Dr. Angelika Eggert

Applicant: Universität Duisburg-Essen

State: Released by ProVendis; Priority date: 21.06.2010

### Genome Network Cancer Genes

Patent number: EP09005492.5; US61/170,375

Title: Development of fluorescently P-loop labeled kinases for screening of inhibitors

Inventor: Rauh, Daniel; Simard, Jeffrey

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Hofgartenstr. 8, 80539 München

State: Pending; Priority date: 17.04.2009

Patent number: EP08013340.8; US61/083,335; EP08020331.7; EP09005493.3

Title: Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds

Inventor: Rauh, Daniel; Simard, Jeffrey; Getlik, Matthäus;

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Hofgartenstr. 8 80539 München; State: Pending; Priority date: 17.04.2009

Patent number: EP09177117.0

Title: Pyrosequencing method for predicting the response of a patient towards anti cancer treatment, European Patent application

Inventor: Altmüller, Nürnberg, Querings

Applicant: Universität zu Köln

State: Pending; Priority date: 25.11.2009

Patent number: EP11164480.3

Title: Blood-based gene detection of non-small cell lung cancer

Inventor: Hofmann, Schultze, Staratschek-Jox, Wolf, Zander

Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn, Universität zu Köln

State: Pending; Priority date: 02.05.2011

Patent number: US 61/529,476; EP11007082.8

Title: Labeled phosphatases for the screening of inhibitors

Inventor: Rauh, Daniel; Simard, Jeffrey; Waldmann, Herbert

Applicant: Max-Planck-Gesellschaft

Priority date: 31.08.2011

Patent number: EP12153907.6

Title: Novel fusion genes in lung cancer

Inventor: Thomas, Roman; Heuckmann, Johannes; Fischer, Florian; Fernandez-Cuesta, Lynnette

Applicant: Max-Planck-Gesellschaft

State: Patent application filed and technology in commercial exploitation;

Priority date: 03.02.2012

### Genome Network Prostate Cancer

Patent number: DE202009008601.1 (**Together with Genome Network Cellular Systems Genomics**)

Title: Inkubationsschale für Hochdurchsatzverfahren bei Protein-Array-Inkubationen  
(Gebrauchsmuster)

Inventor: Mannsperger, Schmidt, Korf, Fink, Kameke

Applicant: DKFZ; Metecon GmbH

State: Published; Priority date: 19.06.2009

SPONSORED BY THE



Federal Ministry  
of Education  
and Research

Patent number: EP09174455.7

Title: Circulating miRNAs as non-invasive markers for diagnosis and staging in prostate cancer  
 Inventor: Jan C. Bräse, Marc Johannes, Thorsten Schlomm, Maria Fälth, Alexander Haese, Thomas Steuber, Tim Beissbarth, Ruprecht Kuner, Holger Sültmann  
 Applicant: DKFZ und Uni Göttingen und Uniklinikum HH-Eppendorf  
 State: Pending; Priority date: 29.10.2009

Patent number: EP 11162979.6

Title: Epigenetische Marker zur Prostata-Tumor-Diagnostik (Prostate cancer markers)  
 Inventor: R. Schweiger, H. Lehrach, S. Börno, H. Sültmann, T. Schlomm, G. Sauter  
 Applicant: Max-Planck-Gesellschaft und DKFZ  
 State: Submitted; Priority date: 19.04.2011

### **Genome Network Colon Cancer**

Patent number: EP12180459.5

Title: Biomarkers for colon cancer  
 Inventor: Schweiger, Michal-Ruth; Grimm, Christina; Herwig, Ralf; Lehrach, Hans  
 Applicant: Max-Planck-Gesellschaft  
 Priority date: 14.08.2012

### **Genome Network Neurodegeneration**

Patent number: EP11161325.3

Title: Phenoxazinones or phenothiazones as inhibitors of amyloid formation  
 Inventor: Wanker, Herbst, Bieschke, Wagner, Wiglenda, Schmidt, Böddrich  
 Applicant: MDC Berlin  
 State: Pending; Priority date: 06.04.2011

### **Genome Network Cellular Systems Genomics**

Patent number: DE202009008601.1 (**Together with Genome Network Prostate Cancer**)

Title: Inkubationsschale für Hochdurchsatzverfahren bei Protein-Array-Inkubationen (Gebrauchsmuster)  
 Inventor: Mannsperger, Schmidt, Korf, Fink, Kameke  
 Applicant: DKFZ; Metecon GmbH  
 State: Published; Priority date: 19.06.2009

Patent number: EP12154916.6

Title: Biomarker set for identifying a severe form of cancer  
 Inventor: Korf, Ulrike; Wiemann, Stefan; Bender, Christian; Sonntag, Johanna  
 Applicant: DKFZ; Priority date: 10.02.2012

### **Genome Network DiGtoP**

Patent number: EP09014709.1, EP09014889.1, US61/264,514, US 61/265,296

Title: Conditional expression of transgenes in vivo  
 Inventor: Laura Schebelé (HMGU), Frank Schnütgen (Uni Frankfurt), Thomas Floss (HMGU)  
 Applicant: Helmholtz Zentrum München, Uni Frankfurt  
 State: Pending; Priority date: 25.11.2009; 30.11.2009; 01.12.2009

Patent number: US61/255,621

Title: Homologous recombination in the oocyte  
 Inventor: Ralf Kühn, Melanie Meyer, Wolfgang Wurst  
 Applicant: Ralf Kühn, Melanie Meyer, Wolfgang Wurst; Helmholtz Zentrum München  
 State: Pending; Priority date: 28.10.2009

SPONSORED BY THE



Patent number: EP10005863.5 / US61/352,103

Title: Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a nonspecific cleavage domain of a restriction nuclease and their use

Inventor: Kühn, Wurst, Meyer

Applicant: Helmholtz Zentrum München

State: Pending; Priority date: 07.06.2010

Patent number: EP11004637.2

Title: Improved Recombination Efficiency by Inhibition of NHEJ DNA Repair

Inventor: Kühn, Wurst

Applicant: Helmholtz Zentrum München

State: Pending, Priority date: 07.06.2011

Patent number: EP11004635.6

Title: Protein having nuclease activity, fusion proteins and uses thereof

Inventor: Kühn

Applicant: Helmholtz Zentrum München

State: Pending, Priority date: 07.06.2011

Patent number: EP10009584.3; 13/823,431 / 10 009 584.3

Title: HOT1 and uses thereof

Inventor: Dr. Dennis Kappei, Prof. Dr. Frank Buchholz, Prof. Dr. Matthias Mann, Dr. Falk Butter

Applicant: Max-Planck-Innovation GmbH

State: Pending; Priority date: 14.09.2010

Patent number: EP12161060.4/ US 61/814,758 (**Together with Genome Network Obesity**)

Title: A novel method of producing an oocyte carrying a modified target sequence in its genome

Inventor: Kühn, Wurst, Meyer

Applicant: Helmholtz Zentrum München

State: Patent application filed and technology in commercial exploitation;

Priority date: 23.03.2012

Patent number: EP131507063.2

Title: Gene editing in the oocyte by Crispr-Cas9 nucleases

Inventor: Kühn, Wurst, Ortiz

Applicant: Helmholtz Zentrum München

State: Pending; Priority date: 15.02.2013

### **Genome Network Environment-related Diseases**

Patent number: PCT/EP2008/008491

Title: Method for identifying an increased susceptibility to ulcerative colitis

Inventor: Schreiber, Franke

Applicant: Universität Kiel

State: Pending, Priority date: 08.10.2008

Patent number: US61/113,342; EP09006623.4-2403

Title: X-chromosomal variation as a diagnostic and therapeutic marker for the progression to AIDS

Inventor: Siddiqui, Roman; Sauermann, Ulrike; Altmüller, Janine; Nürnberg, Peter; Fritzer, Elfriede; Nothnagel, Michael; Krawczak, Michael; Platzer, Mathias

Applicant: Deutsches Primatenzentrum GmbH; Leibniz-Institut für Altersforschung Fritz-Lipmann-Institut e.V.; Universität zu Köln; Christian-Albrechts-Universität zu Kiel

State: Pending; Priority date: 11.11.2008, 15.05.2009

SPONSORED BY THE



Federal Ministry  
of Education  
and Research

### Innovation Alliance Anti-malarial Agents

Patent number: US61/110,217

Title: Use of inhibitors of host kinases for the treatment of infectious diseases

Inventor: Hannus, Martin, Mota, Prudencio, Rodrigues

Applicant: Cenix BioScience GmbH, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa

State: Pending; Priority date: 31.10.2008

### Innovation Alliance Metabolomic Signatures of Heart Failure

Patent number: US61/299,360; EP10000915.8

Title: Means and methods for diagnosing heart failure in a subject

Inventor: Fuhrmann, Reszka, Kastler, Busch, Leibold, Katus, Frey, Weis, Wolf

Applicant: Metanomics GmbH und Universität Heidelberg

State: Pending; Priority date: 29.01.2010

### Innovation Alliance New Tools CVD

Patent number: EP09171773.6

Title: Vasoactive peptide and derivatives thereof

Inventor: Prof. Dr. J. Jankowski, Dr. V. Jankowski, Prof. Dr. W. Zidek, Dr. A. Kretschmer, Prof. Dr. R. Santos, Prof. Dr. M. van der Giet

Applicant: Bayer Schering Pharma AG, Charité Universitätsmedizin Berlin

State: Pending; Priority date: 30.09.2009

### Innovation Alliance WTA Amplification Methods for Biobanks

Patent number: DE102009024143.4

Title: Amplifikation komplexer Nukleinsäuren

Inventor: Korfhage, Fisch

Applicant: Qiagen GmbH

State: Pending; Priority date: 04.06.2009

SPONSORED BY THE



Federal Ministry  
of Education  
and Research

## 5. Research Awards 2008 - 2013

### Science awards for outstanding research

In addition to publications, research awards are an important indicator for scientific success. For their work NGFN scientists received a number of awards ranging from international research fellowships to awards for individual scientific achievements. During the reporting period, 62 NGFN scientists received for their work research awards which are listed below. Additionally, 18 young academics had been awarded prices for posters presented at scientific meetings.

#### Genome Network Obesity

- 2012 Fischer-Posovszky P., Wabitsch M.: Jürgen-Bierich-Preis, Wissenschaftspris der Deutschen Gesellschaft für Kinderendokrinologie und -diabetologie (DGKED) e. V.
- 2011 Hinney A.: August-Homburger Preis der Universität Würzburg für herausragende Arbeiten und Forschungsleistungen im Bereich der Kinder- und Jugendpsychiatrie und Psychotherapie
- 2009 Wissenschaftspris der Dr. mult. Heinz Bürger-Büsing-Stiftung 2009
- 2008 Fischer J.: Forschungspris der Dr. Günther- und Imme-Wille-Stiftung 2008: Dr. Julia Fischer, Institut für Entwicklungs- und Molekularbiologie der Tiere
- 2008 Wabitsch M.: Wissenschaftspris der Stadt Ulm 2008 zur Arbeit „Charakterisierung der Folgestörungen einer vermehrten Fettmasse im Kindesalter.“

#### Genome Network Heart Failure and Innovation Alliance Subgenome Fractionation

- 2011 Streckfuß-Bömeke K.: Wissenschaftspris der Segnitz-Ackermann-Stiftung für Forschung auf dem Gebiet der Herz-Kreislauf-Erkrankungen „Generierung von Patienten-spezifischen induzierten pluripotenten Stammzellen aus Haarkeratinozyten“. Jahrestagung der Nordwestdeutschen Gesellschaft für Innere Medizin 2011
- 2011 Streckfuss-Bömeke K.: 2. Preis, ESC Young Investigators Award for Basic Science 2011 „Generation of patient-specific induced pluripotent stem cells from plucked hair follicle-derived keratinocytes.“
- 2010 Meder B.: Wilhelm P. Winterstein-Preis der Deutschen Herzstiftung

#### Genome Network Herpes virus infection

- 2011 Meister G.: Schering Young Investigator Award im Rahmen der „Molecular Life Sciences 2011“, der Jahrestagung der Gesellschaft für Biochemie und Molekularbiologie, Frankfurt am Main
- 2011 Dölken L.: Robert-Koch-Postdoktoranden-Preis für das Fach Virologie

#### Genome Network RNomics in infection

- 2010 Vogel J.: VAAM Research Award 2010, Vereinigung für Allgemeine und Angewandte Mikrobiologie, Überreicht bei der VAAM-Jahrestagung in Hannover

SPONSORED BY THE



### **Genome Network Leukemia**

- 2011 Hof J.: Medical Faculty Berlin Rising Star-Award of the Molecular Cancer Research Center of the Charité - Medical Faculty Berlin 2011 für die Arbeit "Mutations and deletions of the TP53 gene predict non-response and poor outcome in first relapse of childhood acute lymphoblastic leukemia."
- 2010 Metzeler K.: Wolfgang Wilmanns Stiftungs-Preis 2010 für Arbeiten zur molekularen Charakterisierung der AML
- 2010 Döhner H.: Heidelberger Anita- und Cuno-Wieland-Preis 2010 für Verdienste um die translationale Krebsforschung

### **Genome Network Brain Tumor**

- 2012 Herold-Mende C.: Wissenschaftspreis für Dr. Benito Campos; Förderpreise der Familie Mehdorn Stiftung: Bereich Neurochirurgische Forschung
- 2010 Licher P.: Wissenschaftspreis der „Wilhelm-Warner“-Foundation

### **Genome Network Neuroblastoma**

- 2009 Otto, T.: Deutscher Studienpreis der Körber-Stiftung
- 2008 Gipp M., Marcus G., Harder N., Suratinee A., Rohr K., König R. & Männer R.: "Accelerating the computation of Haralick's Texture Features using Graphics Processing Units (GPUs)." Best Paper Award of the Conference, Proceedings of the World Congress on Engineering, London, U.K., 2-4 July 2008

### **Genome Network Oncogene**

- 2013 Thomas R.: Deutscher Krebspreis 2013 der Deutschen Krebsgesellschaft - Bereich translationale Krebsforschung zum Thema Lungenkrebs
- 2010 Rauh D.: Innovationspreis in Medizinisch und Pharmazeutischer Chemie der Gesellschaft Deutscher Chemiker e.V. (GDCh)

### **Genome Network Alzheimer's Disease**

- 2010 Haass C.: Ehrendoktorwürde der Universität Zürich, 2010
- 2010 Jucker M.: Soriano Lectureship 2010 of the American Neurological Association, Minneapolis, USA
- 2008 Wanker E, Stelzl U, Häning C, Futschik M, Chaurasia G.: Erwin Schrödinger Preis 2008. Jahrestagung 2008 der Helmholtz-Gemeinschaft Deutscher Forschungszentren „Helmholtz international – Themen für die Welt“, Berlin
- 2008 Müller U.: Alzheimer Forschungspreis 2008 der Hans und Ilse Breuer Stiftung für die Arbeit „Die biologische Funktion des beta-Amyloid Precursor Proteins und seiner propeptolytischen Spaltprodukte.“

### **Genome Network Epilepsy and Migraine**

- 2013 Lerche H.: Wissenschaftspreis Alfred-Hauptmann-Preis für Epilepsieforschung für Prof. Dr. Y. G. Weber für die Arbeit Schubert et al, Hum Mutat. 2012;33:1439-43

SPONSORED BY THE



- 2012 Dichgans M: Wolffram-Preis der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG) für PD Dr. Tobias Freilinger für die Arbeit Freilinger et al, Nat Gebet 2012; 44(7):777-82
- 2010 Kubisch C.: Early Career Award der Leopoldina

#### **Genome Network Schizophrenia (MooDS)**

- 2010 Cichon S, Treutlein J, Ridinger M.: Feuerlein Preis 2010 der Oberbergstiftung Matthias Gottschaldt und der Deutschen Gesellschaft für Suchtforschung und Suchttherapie für die Arbeit „Genome-wide association study of alcohol dependence.”, Verleihung beim 3. Deutschen Suchtkongress
- 2009 Nöthen M., Müller-Myhsok B.: Hermann-Emminghaus-Preis
- 2009 Meyer-Lindenberg A.: NARSAD Distinguished Investigator Award 2009 für die Arbeit „Identifying risk mechanisms for schizophrenia through combining genome-wide association and multimodal imaging.”

#### **Genome Network Neurodegenerative Diseases (NeuroNet)**

- 2008 Wanker E., Stelzl U.: Erwin-Schrödinger-Preis 2008 für "The First Protein Interaction Networks for Human in Health and Disease"

#### **Genome Network Parkinson's Disease**

- 2012 Klein C.: Junior Award for Clinical Research der Movement Disorders Society anlässlich der 16. Internationalen Jahrestagung in Dublin, Irland (2012) für Grünewald Dr. rer. nat. Anne
- 2012 Klein C.: cand. med. Björn Arns erhält Uschi Tschabitzer Preis für Junge Neurologen. 16. Jahrestagung der European Federation of the Neurological Sciences, Stockholm Schweden 2012
- 2012 Klein C.: Aufnahme von cand. med. Anna Göbel in die Studienstiftung des Deutschen Volkes
- 2011 Schneider S.: American Academy of Neurology John Stolk Award for Movement Disorders
- 2011 Gasser T.: K. J. Zülch Preis der Max-Planck-Gesellschaft
- 2011 Schmidt A.: Junior Award der Movement Disorder Society 2011
- 2010 Gasser T.: Dingebauer Preis der Deutschen Gesellschaft für Neurologie
- 2010 Grünewald A.: Reisebeihilfe des Boehringer Ingelheim Fonds für einen Forschungsaufenthalt an der Universität Sydney, Australien (2010) zur Charakterisierung der mitochondrialen Funktion in Fibroblasten von Patienten mit rezessiven Parkinson-Syndromen
- 2009 Seibler P.: Einjähriges DAAD-Stipendium zur Generierung von dopaminergen Neuronen aus Fibroblasten von Patienten mit rezessiven Parkinson-Syndromen an der MS der Harvard Medical School, Boston, USA.
- 2009 Pichler I.: Auslandsforschungsstipendium des DAAD für einen Aufenthalt von Dr. Pichler (Italien) an der Sektion für Klinische und Molekulare Neurogenetik an der Klinik für Neurologie, Universität zu Lübeck (2009) „Untersuchung von Apoptose in Fibroblasten von Parkinsonpatienten mit Mutationen in rezessiven Parkinson-Genen“
- 2008 Klein C., „Career development award“ der Hermann und Lilly Schilling-Stiftung zur Einrichtung einer Sektion für Klinische und Molekulare Neurogenetik an der Klinik für Neurologie der Universität zu Lübeck

SPONSORED BY THE



### **Genome Network Mental Retardation (MRNET)**

- 2012 Rappold G.: Akademie Preis 2012 der Heidelberger Akademie der Wissenschaften
- 2009 Zweier C.: Trainee Research Award in der Kategorie Postdoctoral Clinical Genetics, Amerikanische Tagung für Humangenetik 2009 für die Arbeit „CNTNAP2 and NRXN1 are mutated in recessive, severe mental retardation resembling Pitt-Hopkins syndrome and target a common synaptic protein in Drosophila. Am J Hum Genet. 2009 85:655-66.“

### **Genome Network Alcohol Addiction**

- 2011 Spanagel R.: AGNP Award for Excellence in Psychopharmacology
- 2010 Spanagel R.: Reinhart-Koselleck-Award
- 2008 Spanagel R.: James B. Isaacson Award

### **Genome Network DiGtoP**

- 2013 Prakash N.: Wissenschaftspris Weihenstephan der Stadt Freising
- 2012 Mann M.: Gottfried Wilhelm Leibniz-Preis der Deutschen Forschungsgesellschaft
- 2012 Mann M.: Körber-Preis
- 2012 Mann M.: Louis-Jeantet Preis für Medizin
- 2012 Mann M.: Ernst Schering Preis
- 2011 Hyman A.: Gottfried Wilhelm Leibniz-Preisträger
- 2010 Stewart F.: Preis der Internationalen Gesellschaft für Transgene Technologien (ISTT)
- 2010 Mann M.: Friedrich Wilhelm Joseph von Schelling-Preis der Bayerischen Akademie der Wissenschaften
- 2009 Mann M.: Ehrendoktorwürde, Universität Dundee, Schottland
- 2008 Mann M.: „HUPO Distinguished Achievement Award in Proteomic Sciences“ (geteilt mit Prof. Denis Hochstrasser)

### **Genome Network MHC Sequencing**

- 2012 Hoehe M.: Nat Methods January 2012 Special Feature: Methods of the Year 2011: Unsere fosmid-basierte Methode zur Haplotypisierung ganzer Genome wurde als eine der vielversprechendsten Methoden des Jahres 2011 gekürt.

### **Genome Network Environment-related Diseases**

- 2012 Kabesch M.: Johannes Wenner Preis 2012 der Deutschen Lungenstiftung für die Arbeiten zur *Genetik beim Asthma bronchiale*
- 2012 Weidinger S.: ADF/ECARF Award (Arbeitsgemeinschaft Dermatologische Forschung & European Center for Allergy Research Foundation) für die Arbeit Paternoster et al, Nat Genet. 2011 December 25; 44(2): 187–192
- 2010 Albrecht M.: HUPO Early Career Investigator Award 2010 by the Human Proteome Organization for outstanding early career researchers. 9th HUPO World Congress, Sydney, Australia, 2010.
- 2010 Esparza-Gordillo J, Weidinger S.: Allergopharma Award 2010

SPONSORED BY THE




## 6. External Cooperation of NGFN-Plus and -Transfer

### The national research network is also internationally connected

The scientific work of NGFN-Plus and NGFN-Transfer in the Program of Medical Genome Research is highly recognized on the national as well as international level. This fact becomes especially obvious when looking at the collaborations of NGFN scientists all over the world that reflects an intense international networking.

Only in Germany, NGFN Scientists are involved in 402 cooperations with different external partners. Additionally they cooperate with 546 research groups in 40 countries worldwide. 54 of these international cooperations are participations at 21 different EU-projects. The geographical distribution of the NGFN partners is shown on the following map.

The number of cooperations is based on the database entries to the NGFN project database until December 31, 2011. All entries made after this day could not be included.




## 7. Academic Education 2008 - 2013

### Passing on the knowledge to the next generation of scientists

The education of young scientists is an important responsibility of academic research. Therefore NGFN-Plus and NGFN-Transfer educate young researchers throughout their diploma theses, dissertation or state doctorates. The allocation of the 960 scientists to these three categories is presented in the following figure.

The diagram shows the sectioning of the total number of 960 scientists in academic training according to these three categories.




SPONSORED BY THE



## 8. Public Relations 2008 - 2013

### The NGFN is present in the public

In addition to the important number of articles published in scientific journals, NGFN-Plus and NGFN-Transfer are also present in the media such as print and online publications (e. g. Süddeutsche Zeitung, FAZ, spiegel.de or biotechnologie.de). Moreover, book publications, reports and comments on radio or TV (e. g. Quarks & Co on WDR), as well as the participation in non-scientific events (e. g. „Lange Nacht der Wissenschaften“) provide information to the public about the work and the achievements of the Program of Medical Genome Research. Quantity and categories of media coverage of NGFN projects are shown below.




SPONSORED BY THE



## 9. Publication History 2001 - 2013

### The NGFN, successful since its foundation

The NGFN was founded in 2001 and has made large contributions to medical genome research in the past 12 years by a huge number of scientific publications. From July 2001 to May 2013, 5,254 scientific articles have been published. Within the first three years of funding during NGFN-1 (7/2001 - 6/2004) 987 publications were released, followed by even 1,822 articles in the subsequent four year funding of NGFN-2 (7/2004 - 6/2008). During the approximately five years of the current funding period already 2,445 scientific articles were released by scientists of NGFN-Plus and NGFN-Transfer in the Program of Medical Genome Research. Since the analysis and publication of the scientific results take a long time, it can be expected that there will be more articles to be published within the next months. The continuously high number of publications that is shared with the international research community proves the great benefit of the sustainable funding strategy pursued by the BMBF.



SPONSORED BY THE

